GoodRx Holdings, Inc. Financial Summary

Quick Answer

GoodRx Holdings, Inc. reported Total Revenue of $796.85 million for fiscal year 2025.

GoodRx Holdings, Inc. — Key Financials by Year

Metric 2025 2024 2023 2022 2021 2020
Total Revenue $796.85M
+0.6%
$792.32M
+5.6%
$750.26M
-2.1%
$766.55M
+2.8%
$745.42M
+35.4%
$550.70M
+41.9%
Revenue (ASC 606) $796.85M
+0.6%
$792.32M
+5.6%
$750.26M
-2.1%
$766.55M
+2.8%
$745.42M
+35.4%
$550.70M
+41.9%
Net Income $30.44M
+85.7%
$16.39M
+284.8%
-$8.87M
+73.0%
-$32.83M
-30.0%
-$25.25M
+91.4%
-$293.62M
-544.6%
Diluted EPS $0.09
+125.0%
$0.04
+300.0%
-$0.02
+75.0%
-$0.08
-33.3%
-$0.06
+94.4%
-$1.07
-694.4%
Total Assets $1.40B
+1.2%
$1.39B
-12.6%
$1.59B
-1.0%
$1.60B
-0.2%
$1.61B
+9.4%
$1.47B
+280.1%
Cash and Equivalents $261.82M
-41.6%
$448.35M
-33.3%
$672.30M
-11.2%
$757.16M
-19.5%
$941.11M
-2.8%
$968.69M
+3618.6%
Long-Term Debt $483.26M
-0.7%
$486.71M
-24.9%
$647.70M
-0.6%
$651.80M
-0.6%
$655.86M
-0.6%
$659.89M
-0.6%
Stockholders Equity $616.26M
-15.0%
$724.66M
-4.9%
$761.96M
-6.5%
$814.83M
-2.0%
$831.68M
+16.9%
$711.36M
+165.4%
R&D Expense $121.03M
-2.2%
$123.75M
-8.9%
$135.84M
-5.1%
$143.14M
+13.7%
$125.86M
+103.6%
$61.82M
+111.0%
Operating Income $87.49M
+32.9%
$65.85M
+343.8%
-$27.01M
-1653.9%
$1.74M
-87.0%
$13.41M
+104.9%
-$275.72M
-297.4%

Most Recent Quarter

Metric Quarter Ending Value YoY QoQ
Total Revenue September 30, 2025 $196.03M +0.4% -3.5%
Revenue (ASC 606) September 30, 2025 $196.03M +0.4% -3.5%
Net Income September 30, 2025 $1.12M -71.8% -91.3%
Diluted EPS September 30, 2025 $0.00 -100.0% -100.0%
Total Assets September 30, 2025 $1.33B -2.2% +0.5%
Cash and Equivalents September 30, 2025 $273.53M -35.5% -2.8%
Long-Term Debt September 30, 2025 $484.11M -0.7% -0.2%
Stockholders Equity September 30, 2025 $600.71M -13.7% -6.6%
R&D Expense September 30, 2025 $31.01M +2.9% +3.6%
Operating Income September 30, 2025 $14.62M -28.4% -45.5%
  • GoodRx Holdings, Inc. reported Total Revenue of $796.85 million for fiscal year 2025.
  • GoodRx Holdings, Inc. showed an increase of +0.6% in Total Revenue compared to the prior fiscal year.
  • GoodRx Holdings, Inc. reported Revenue (ASC 606) of $796.85 million for fiscal year 2025.
  • GoodRx Holdings, Inc. showed an increase of +0.6% in Revenue (ASC 606) compared to the prior fiscal year.
  • GoodRx Holdings, Inc. reported Net Income of $30.44 million for fiscal year 2025.
  • GoodRx Holdings, Inc. showed an increase of +85.7% in Net Income compared to the prior fiscal year.
  • GoodRx Holdings, Inc. reported Diluted EPS of $0.09 per share for fiscal year 2025.
  • GoodRx Holdings, Inc. showed an increase of +125.0% in Diluted EPS compared to the prior fiscal year.
  • GoodRx Holdings, Inc. reported Total Assets of $1.40 billion for fiscal year 2025.
  • GoodRx Holdings, Inc. showed an increase of +1.2% in Total Assets compared to the prior fiscal year.
  • GoodRx Holdings, Inc. reported Cash and Equivalents of $261.82 million for fiscal year 2025.
  • GoodRx Holdings, Inc. showed a decrease of -41.6% in Cash and Equivalents compared to the prior fiscal year.
  • GoodRx Holdings, Inc. reported Long-Term Debt of $483.26 million for fiscal year 2025.
  • GoodRx Holdings, Inc. showed a decrease of -0.7% in Long-Term Debt compared to the prior fiscal year.
  • GoodRx Holdings, Inc. reported Stockholders Equity of $616.26 million for fiscal year 2025.
  • GoodRx Holdings, Inc. showed a decrease of -15.0% in Stockholders Equity compared to the prior fiscal year.
  • GoodRx Holdings, Inc. reported R&D Expense of $121.03 million for fiscal year 2025.
  • GoodRx Holdings, Inc. showed a decrease of -2.2% in R&D Expense compared to the prior fiscal year.
  • GoodRx Holdings, Inc. reported Operating Income of $87.49 million for fiscal year 2025.
  • GoodRx Holdings, Inc. showed an increase of +32.9% in Operating Income compared to the prior fiscal year.
  • All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.

Last verified:

Leave a Comment